Eupraxia Pharmaceuticals announced encouraging data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data showed that patients receiving 20 injections of EP-104GI experienced significant improvements in the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), indicating reduced inflammation and fibrosis in the esophagus. This dosing regimen is now being studied in the placebo-controlled Phase 2b trial, with top-line results expected in Q4 2026. These findings suggest EP-104GI could offer a promising new treatment for EoE, a condition causing esophageal inflammation and swallowing difficulties.
Backpack has introduced the first-ever 24/7 trading platform for real U.S. equities, allowing international investors to buy and sell stocks like SpaceX, Micron, and SanDisk around the clock. Unlike synthetic derivatives, these are actual equities wi...
BingX, a major crypto exchange, introduced the BingX Visa Debit Card in partnership with Wirex, allowing users to spend digital assets globally through Visa's payment network. The card supports purchases, ATM withdrawals, and automatic currency conve...
Independent proxy advisory firms, including ISS, recommend Equinox Gold shareholders vote in favor of the proposed merger with Orla Mining, which aims to create a leading North American gold producer. The combined company is expected to produce 1.1 m...
The generative AI market in the oil and gas sector is projected to grow from $0.53 billion in 2025 to $1.15 billion by 2030, at a CAGR of 16.9%. Growth is driven by adoption of cloud-based AI for real-time monitoring, predictive maintenance, and dril...
Sigenergy, Australia's leading home battery brand, has introduced a $1,000 discount on its new 9kWh SigenStor battery modules. This discount can be stacked with the Federal Government’s Cheaper Home Batteries Program rebate, potentially allowing hous...
